Molecular mechanisms of opiate and cocaine addiction

Current Opinion in Neurobiology

Volumn 7, Issue 5, 1997, Pages 713-719

  Nestler, Eric J ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CELL RECEPTOR; COCAINE; CYCLIC AMP; DOPAMINE; ENZYME; GUANINE NUCLEOTIDE BINDING PROTEIN; OPIATE; PROTEIN KINASE; TRANSCRIPTION FACTOR;

BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG TOLERANCE; GENE EXPRESSION; HUMAN; LOCUS CERULEUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SECOND MESSENGER;

EID: 0030727775     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-4388(97)80094-3     Document Type: Article

References (71)

1. ••].
2. ••] provide a timely review of the types of animal models that are now available to study the neurobiology of drug addiction. The mounting evidence for an important role played by the mesolimbic dopamine system in mediating the reinforcing actions of drugs of abuse is summarized. In addition, the reviews highlight recent results that implicate other brain regions, particularly the amygdala, in negative motivational aspects of drug addiction.
3. Sharma SK, Klee WA, Nirenberg M: Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 1975, 72:3092-3096.
4. Nestler EJ, Hope BT, Widnell K: Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993, 11:995-1006.
5. Koob GF, Maldonado R, Stinus L: Neural substrates of opiate withdrawal. Trends Neurosci 1992, 15:186-191.
6. Nestler EJ: Under seige: the brain on opiates. Neuron 1996, 16:897-900. Summarizes the hypothesis that upregulation of the cAMP pathway in discrete brain regions represents one mechanism of opiate tolerance and dependence. Upregulation of the cAMP pathway in the locus coeruleus has been related directly to electrophysiological adaptations induced by opiates in these neurons, which, in turn, have been related to somatic opiate dependence. In contrast, upregulation of the cAMP pathway in the nucleus accumbens has been related to motivational aspects of addiction to opiates and other drugs of abuse.
7. Lane-Ladd SB, Pineda J, Boundy V, Pfeuffer T, Krupinski J, Aghajanian GK, Nestler EJ: CREB in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. J Neurosci 1997, 17:7890-7901. Demonstrates that chronic morphine administration selectively upregulates two forms of adenylyl cyclase in the locus coeruleus, along with the catalytic and type II regulatory subunits of PKA. By infusing antisense oligonucleotides to CREB directly into the locus coeruleus, which decreases CREB levels in this region, the authors show that the morphine-induced upregulation of adenylyl cyclase, but not of PKA, is dependent on CREB function. They relate these biochemical findings to electrophysiological adaptations in locus coeruleus neurons and to behavioral signs of somatic opiate withdrawal.
8. Kogan JH, Nestler EJ, Aghajanian GK: Elevated basal firing rates of locus coeruleus neurons in brain slices from opiatedependent rats: association with enhanced responses to 8-Br-cAMP. Eur J Pharmacol 1992, 211:47-53.
9. Alreja M, Aghajanian GK: QX-314 blocks the potassium but not the sodium-dependent component of the opiate response in LC neurons. Brain Res 1994, 639:320-324.
10. •]).
11. Terwilliger RZ, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ: A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 1991, 548:100-110.
12. Ortiz J, Fitzgerald LW, Charlton M, Lane S, Trevisan L, Guitart X, Shoemaker W, Duman RS, Nestler EJ: Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 1995, 21:289-298.
13. Unterwald E, Fillmore J, Kreek M: Chronic repeated cocaine administration increases dopamine D1 receptor-mediated signal transduction. Eur J Pharmacol 1996, 318:31-35.
14. Henry DJ, White FJ: The persistence of behavioral sensitization to cocaine parallels enhanced inhibition of nucleus accumbens neurons. J Neurosci 1995, 15:6287-6299.
15. + channels. Interestingly, these effects (of stimulant exposure) could be mediated, at least in part, via the upregulated cAMP pathway observed under these conditions.
16. Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 1995, 18:463-495.
17. Kelley A, Holahan M: Enhanced reward related responding following cholera toxin infusion into the nucleus accumbens. Synapse 1997, 26:46-54. This paper and [16] provide direct evidence that the cAMP pathway in the nucleus accumbens modulates the reinforcing properties of stimulants. Self and Nestler [16], using the drug self-administration paradigm, provide evidence that inhibition of the cAMP pathway increases the reinforcing properties of cocaine and can induce relapse to cocaine-seeking behavior. In contrast, Kelley and Holahan [17•], using the conditioned reinforcement paradigm, provide evidence that activation of the cAMP pathway increases the reinforcing properties of stimulants. These paradoxical findings clearly indicate the need for further study, but also highlight the importance of utilizing several complementary behavioral methods to infer modulation of reinforcement mechanisms in laboratory animals.
18. Cunningham ST, Kelley AE: Hyperactivity and sensitization to psychostimulants following cholera toxin infusion into the nucleus accumbens. J Neurosci 1993, 13:2342-2350.
19. Miserendino MJD, Nestler EJ: Behavioral sensitization to cocaine: modulation by the cyclic AMP system in the nucleus accumbens. Brain Res 1995, 674:299-306.
20. Bonci A, Williams J: A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron 1996, 16:631-639.
21. Bonci A, Williams J: Increased probability of GABA release during withdrawal from morphine. J Neurosci 1997, 17:796-803. The authors elaborate a scheme of opiate action in the ventral tegmental area, wherein opiates induce adaptations in GABAergic neurons, which then influence the functioning of the dopaminergic neurons in this region during a course of chronic morphine treatment and withdrawal. Evidence for a role of the cAMP pathway in these adaptations is presented.
22. Tolliver B, Ho L, Reid M, Berger S: Evidence for involvement of ventral tegmental area cyclic AMP systems in behavioral sensitization to psychostimulants. J Pharmacol Exp Ther 1996, 278:1-10. This paper provides further evidence that modulation of the cAMP pathway in the ventral tegmental area can affect mesolimbic dopamine function and behavioral responses to drugs of abuse. Specifically, the authors show that infusion of PKA inhibitors directly into the ventral tegmental area can attenuate the development of locomotor sensitization to stimulants.
23. Hyman S: Addiction to cocaine and amphetamine. Neuron 1996, 16:901-904. Provides an overview of the actions of cocaine and amphetamine on gene expression, particularly within the nucleus accumbens and related striatal regions. The author advances the hypothesis that stimulant-induced upregulation of prodynorphin expression in these regions may contribute to an aversive state during early phases of drug withdrawal. The role of specific transcription factors, particularly CREB and immediate early gene products, in mediating these effects is discussed.
24. Spangler R, Zhou A, Maggos C, Yuferov V, Kreek M: Regulation of kappa opioid receptor mRNA in the rat brain by 'binge' pattern cocaine administration and correlation with preprodynorphin mRNA. Mol Brain Res 1996, 38:71-76. The authors demonstrate that repeated administration of cocaine results in the regulation of endogenous opioid systems, both opioid peptides and opioid receptors. Their hypothesis is that such regulation contributes to the functional changes in the mesolimbic dopamine system seen in the chronic drug-treated state. This paper also describes a 'binge' pattern of cocaine administration modeled after human cocaine use, in which repeated doses of cocaine are given over a relatively short time span.
25. Loh HH, Smith AP: Molecular characterization of opioid receptors. Annu Rev Pharmacol Toxicol 1990, 30:123-147.
26. ••].
27. ••] represent the evolving view that agonist exposure can desensitize opioid receptor function by inducing receptor internalization, which can occur relatively rapidly, consistent with a role for this process in mediating acute desensitization phenomena. A major question, now under investigation, is the mechanism (e.g. receptor phosphorylation) by which this internalization occurs. Current research also aims to understand the differential ability of various opioid receptor agonists in inducing this internalization.
28. Freedman NJ, Lefkowitz RJ: Desensitization of G protein-coupled receptors. Recent Prog Horm Res 1996, 51:319-351. Provides an updated discussion of the several types of mechanisms that can contribute to desensitization of G-protein-coupled receptors in vitro. A major challenge of future research, in relating this work to the field of drug addiction, is to determine which of these mechanisms operate for opioid receptors, to identify the specific populations of neurons in vivo in which the mechanisms occur, and to determine whether adaptations in any of these various mechanisms contribute to opiate tolerance.
29. Pei G, Kieffer BL, Lefkowitz RJ, Freedman NJ: Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C. Mol Pharmacol 1995, 48:173-177.
30. Arden JR, Segredo V, Wang Z, Lameh J, Sadee W: Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 1995, 65:1636-1645.
31. Zhang L, Yu Y, Mackin S, Weight F, Uhl GR, Wang JB: Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J Biol Chem 1996, 271:11449-11454. This paper and other recent work (A Kovoor et al., personal communication) are examples of several recent reports that opioid receptors can undergo phosphorylation and that such phosphorylation can, under certain circumstances, functionally desensitize the receptors. Several protein kinases are implicated, particularly GRKs and their associated arrestin proteins, as well as protein kinase C. Current research is aimed at identifying the precise effect of phosphorylation on receptor function and the specific types of phosphorylation reactions that occur in the brain in vivo.
32. Terwilliger RA, Ortiz J, Guitart X, Nestler EJ: Chronic morphine administration increases β-adrenergic receptor kinase (βARK) levels in the rat locus coeruleus. J Neurochem 1994, 63:1983-1986.
33. Van Vliet BJ, Van Rijswijk AL, Wardeh G, Mulder AH, Schoffelmeer AN: Adaptive changes in the number of Gs- and Gi-proteins underlie adenylyl cyclase sensitization in morphine-treated rat striatal neurons. Eur J Pharmacol 1993, 245:23-29.
34. i α subunits observed in this brain region after morphine exposure and suggests a functional uncoupling of opioid receptors from their G-protein subunits in the tolerant state.
35. Boekhoff I, Touhara K, Danner S, Inglese J, Lohse MJ, Breer H, Lefkowitz RJ: Phosducin, potential role in modulation of olfactory signaling. J Biol Chem 1997, 272:4606-4612.
36. Dohlman HG, Thorners J: RGS proteins and signaling by heterotrimeric G proteins. J Biol Chem 1997, 272:3871-3874. See annotation [37••].
37. ••].
38. Kovoor A, Henry DJ, Chavkin C: Agonist-induced desensitization of the mu opioid receptor-coupled potassium channel (GIRK1). J Biol Chem 1995, 270:589-595.
39. ••].
40. i α signaling, opiates can activate adenylyl cyclase as well as the phosphatidylinositol pathway via other G proteins in certain cell types. The authors provide evidence that such excitatory effects of opiates are upregulated after chronic opiate administration and may thereby contribute to a state of tolerance by opposing the inhibitory actions of the drug.
41. Kalivas PW, Stewart J: Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 1991, 16:223-244.
42. Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993, 18:247-291.
43. Shaham Y, Rajabi H, Stewart J: Relapse to heroin-seeking in rats under opioid maintenance: the effects of stress, heroin priming, and withdrawal. J Neurosci 1996, 16:1957-1963.
44. Cunningham ST, Kelley AE: Evidence for opiate-dopamine cross-sensitization in nucleus accumbens: studies of conditioned reward. Brain Res Bull 1992, 29:675-680.
45. Stewart J, Vezina P: A comparison of the effects of intra-accumbens injections of amphetamine and morphine on reinstatement of heroin intravenous self-administration behavior. Brain Res 1988, 457:287-294.
46. White FJ, Hu X-T, Zhang X-F, Wolf ME: Repeated administration of cocaine or amphetamine alters neuronal responses to glutamate in the mesoaccumbens dopamine system. J Pharmacol Exp Ther 1995, 273:445-454.
47. Fitzgerald LW, Ortiz J, Hamedani AG, Nestler EJ: Regulation of glutamate receptor subunit expression by drugs of abuse and stress: common adaptations among cross-sensitizing agents. J Neurosci 1996, 16:274-282.
48. Carlezon WA Jr, Boundy VA, Haile CN, Kalb RG, Neve R, Nestler EJ: Sensitization to morphine induced by viral-mediated gene transfer. Science 1997, 277:812-814. The authors use recombinant herpes simplex virus vectors to overexpress glutamate type 1 receptor (GluR1) or other AMPA glutamate receptor subunits specifically in the ventral tegmental area. They show that overexpression of GluR1 specifically results in sensitized locomotor and reinforcing responses to morphine. Importantly, viral infection is transient and not associated with detectable toxicity. The results support the hypothesis that drug-induced upregulation of GluR1 in this brain region is one mechanism of drug sensitization. They also support the use of viral-mediated gene transfer to establish the molecular mechanisms underlying the complex behaviors of addiction.
49. Maggos C, Spangler R, Zhou Y, Schlussman S, Ho A, Kreek M: Quantitation of dopamine transporter mRNA in the rat brain: mapping effects of "binge" cocaine administration and withdrawal. Synapse 1997, 26:55-61.
50. Cerruti C, Pilotte NS, Uhl G, Kuhar MJ: Reduction in dopamine transporter mRNA after cessation of repeated cocaine administration. Mol Brain Res 1994, 22:132-138.
51. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemannn R, Gatley SJ, MacGregor RR, Wolf AP: Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 1996, 14:159-168.
52. Malison RT, Best SE, Wallace EA, McCance E, Laruelle M, Zoghbi SS, Baldwin RM, Seibyl JS, Hoffer PB, Price LH et al.: Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology 1995, 122:358-362.
53. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612. This paper describes the generation, by homologous recombination, of mice lacking the dopamine transporter. The mice show marked increases in base-line locomotor activity, but no additional increase in response to acute administration of cocaine or amphetamine. The results support the important role played by the dopamine transporter in mediating the acute locomotor-activating effects of these stimulants. More significantly, the mice provide a unique system in which to determine the extent to which other effects of the drugs, particularly reinforcement and craving, are mediated by distinct mechanisms (e.g. inhibition of the serotonin or norepinephrine transporters). The mice also provide a unique system in which to study the brain's long-term adaptations to primary defects in the regulation of dopaminergic neurotransmission.
54. Lu W, Chen H, Xue C, Wolf M: Repeated amphetamine administration alters the expression of mRNA for AMPA receptor subunits in rat nucleus accumbens and prefrontal cortex. Synapse 1997, 26:269-280.
55. Lucas JJ, Segu L, Hen R: 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol Pharmacol 1997, 51:755-763. This paper demonstrates abnormal responses to cocaine in mice lacking the serotonin 1B receptor. The work highlights the important role played by neurotransmitter systems other than dopamine in mediating the complex effects of drugs of abuse on brain function.
56. 2+ pathways in mediating this cellular form of reinforcement is discussed.
57. Guitart X, Thompson MA, Mirante CK, Greenberg ME, Nestler EJ: Regulation of CREB phosphorylation by acute and chronic morphine in the rat locus coeruleus. J Neurochem 1992, 58:1168-1171.
58. Widnell KL, Russell D, Nestler EJ: Regulation of cAMP response element binding protein in the locus coeruleus in vivo and in a locus coeruleus-like (CATH.a) cell line in vitro. Proc Natl Acad Sci USA 1994, 91:10947-10951.
59. Maldonado R, Blendy JA, Tzavara E, Gass P, Roques BP, Hanoune J: Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 1996, 273:657-659. The authors generated mice deficient in the major forms of CREB, α and δ, by homologous recombination and demonstrated that they exhibit attenuated behavioral signs of somatic opiate withdrawal. The results thereby support a role for CREB in mediating some of the long-term adaptations to chronic opiate exposure. It will be interesting to determine whether other responses to opiates, particularly motivational adaptations, are similarly attenuated. The mice also provide a model system in which to identify some of the target genes through which CREB produces these effects. One limitation of the mice is that they do not provide information on the specific brain regions involved in opiate action, as the CREB deficiency is expressed ubiquitously.
60. Cole RL, Konradi C, Douglass J, Hyman SE: Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 1995, 14:813-823.
61. •] demonstrate a reduction in levels of CREB immunoreactivity and in CRE-binding activity in the nucleus accumbens after chronic morphine administration. The apparent discrepancies in these findings could be attributable to the different drugs, drug treatment regimens (e.g. intermittent versus continuous), or brain regions involved. These studies highlight the need for further research to more precisely define the way in which CREB is regulated by chronic drug exposure and to determine the functional (electrophysiological, behavioral) consequences of such regulation.
62. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, Nestler EJ: Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994, 13:1235-1244.
63. Chen J, Kelz MB, Hope BT, Nakabeppu Y, Nestler EJ: Chronic Fos-related antigens: stable variants of ΔFosB induced in brain by chronic treatments. J Neurosci 1997, 17:4933-4941.
64. Hiroi N, Brown J, Haile C, Ye H, Greenberg ME, Nestler EJ: FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and abnormality in locomotor and reinforcing responses to cocaine. Proc Natl Acad Sci USA 1997, 94:10397-10402. This paper definitively identifies long-lasting Fos-like proteins induced in nucleus accumbens and related striatal regions in response to chronic cocaine or morphine administration as isoforms of ΔFosB, a truncated splice variant of FosB (see also [63,65]). The behavioral significance of drug-induction of this transcription factor is demonstrated by sensitized responses to the locomotor-activating and reinforcing properties of cocaine in fosB knockout mice. A major challenge for future investigations is to identify the specific target genes through which changes in levels of ΔFosB lead to altered functioning of nucleus accumbens and other striatal neurons and, eventually, to modulation of behavioral responses to drugs of abuse.
65. Mandelzys A, Gruda MA, Bravo R, Morgan JI: Absence of a persistently elevated 37 kDa Fos-related antigen and AP-1-like DNA-binding activity in the brains of kainic acid-treated fosB null mice. J Neurosci 1997, 17:5407-5415.
66. Reid M, Hsu K, Tolliver B, Crawford C, Berger P: Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitization. J Pharmacol Exp Ther 1996, 276:1244-1256.
67. Cha X, Pierce R, Kalivas P, Mackler S: NAC-1: a rat brain mRNA increased in the nucleus accumbens three weeks after chronic cocaine self-administration. J Neurosci 1997, in press.
68. Fosnaugh J, Bhat R, Yamagata K, Worley P, Baraban J: Activation of arc, a putative "effector" immediate early gene, by cocaine in rat brain. J Neurochem 1995, 64:2377-2380.
69. Iwata S, Hewlett G, Gnegy M: Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes. Synapse 1997, 26:281-291.
70. 2-MPTP on serotonergic and noradrenergic nerve terminals. Mol Pharmacol 1996, 50:1511-1519.
71. Steketee JD, Striplin CD, Murray TF, Kalivas PW: Possible role for G-proteins in behavioral sensitization to cocaine. Brain Res 1991, 545:287-291.